ARWR supply chain intelligence for Arrowhead Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| RPRX | Royalty Pharma plc | 85% | Reciprocal relationship from RPRX graph: Reciprocal relationship from ARWR graph: In consideration for the payment of the foregoing amounts under the Royalty Pharma Agreement, Royalty Pharma is entit… |
| RPRX | Royalty Pharma plc | 85% | In consideration for the payment of the foregoing amounts under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the O… |
| VISIRNA-THERAPEUTICS-INC | VISIRNA-THERAPEUTICS-INC | 80% | On August 1, 2025, Visirna Therapeutics HK Limited (“Visirna HK”), a wholly owned subsidiary of Visirna Therapeutics, Inc, a majority owned subsidiary of the Company, entered into an Asset Purchase A… |
| DYN | Dyne Therapeutics, Inc. | 72% | Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number… |
| IBIO | iBio, Inc. | 72% | Reciprocal relationship from IBIO graph: t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. Ther… |
| IONS | Ionis Pharmaceuticals, Inc. | 72% | Reciprocal relationship from IONS graph: h arrangements with collaborative partners or others, which could require us to give up rights to certain of our technologies or medicines. We have incurred l… |
| SRPT | Sarepta Therapeutics, Inc. | 72% | Reciprocal relationship from SRPT graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from SRPT g… |
| 180-DAYS-WRITTEN-NOTICE | 180-DAYS-WRITTEN-NOTICE | 70% | Collaboration Agreement with 180 days' written notice to the Company if terminated after any regulatory approval of a licensed product |
| 30-DAYS-WRITTEN-NOTICE | 30-DAYS-WRITTEN-NOTICE | 70% | Collaboration Agreement with 30 days' written notice to the Company if terminated prior to any regulatory approval of a licensed product |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| NVS | Novartis AG | 92% | Reciprocal relationship from NVS graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from NVS graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from NVS grap… |
| NVS | Novartis AG | 92% | For the three months ended March 31, 2026, the Company recorded $ 20.5 million in revenue from Novartis. |
| SAREPTA | SAREPTA | 90% | During the six months ended March 31, 2026, the Company recorded $271.2 million in revenue. |
| SANOFI | SANOFI | 85% | partially offset by increased revenue from Novartis and Sanofi, reflecting the timing and progress of the Company’s respective collaboration and license agreements. |
| SNYNF | Sanofi | 85% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from SNYN… |
| SNYNF | Sanofi | 85% | nded September 30, 2025. RESULTS OF OPERATIONS The following data summarizes the Company’s results of operations for the following periods indicated: Three Months Ended March 31, Six Months Ended Mar… |
| AMGN | Amgen Inc. | 80% | Reciprocal relationship from AMGN graph: Reciprocal relationship from ARWR graph: The Company remains eligible to receive any milestone payments potentially payable by Amgen under the Olpasiran Agreement. |
| AMGN | Amgen Inc. | 80% | The Company remains eligible to receive any milestone payments potentially payable by Amgen under the Olpasiran Agreement. |
| SRPT | Sarepta Therapeutics, Inc. | 80% | Reciprocal relationship from SRPT graph: past several years to further enhance our internal research and development capabilities. However, we currently do not have internal GMP manufacturing capabil… |
| DYN | Dyne Therapeutics, Inc. | 72% | Reciprocal relationship from DYN graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from DYN graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from DYN grap… |
| IBIO | iBio, Inc. | 72% | Reciprocal relationship from IBIO graph: Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc., Terns Pharmaceuticals, Inc., Skye Biosc… |
| IONS | Ionis Pharmaceuticals, Inc. | 72% | Reciprocal relationship from IONS graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from IONS graph: vestigators, contract research organizations and other third-party service p… |
| VKTX | Viking Therapeutics, Inc. | 72% | Reciprocal relationship from VKTX graph: y a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinica… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| ARWR-DEBT | Debt stack $1.4B | 90% | Market cache reports total debt of $1.4B. |
| ARWR-DEBT-58576 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2026-03-31. |
| ARWR-DEBT-7864 | Warrants outstanding: 917441 | 90% | xbrl warrant detail from xbrl 2025-09-30. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| ARWR-OWNER-AVORO-CAPITAL-ADVISORS-LLC | Avoro Capital Advisors LLC | 90% | 13F overlay lists Avoro Capital Advisors LLC as top holder; 441 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| BCYC | Bicycle Therapeutics plc | 100.00 | 2 | |
| DYN | Dyne Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| WHWK | Whitehawk Therapeutics, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 |